Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Furthermore, we detected significant inverse associations of Afamin with complement C3, serum albumin, hemoglobin, and 25(OH)-Vitamin D3 levels (Table 3).
Source: Correlation of urine/plasma Afamin with different clinical and laboratory manifestations in LN patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All participants were recruited from Nanjing Drum Tower Hospital.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Urine Afamin as a biomarker of lupus nephritis
Study design awaiting verification · Frontiers in Immunology · 2025
Original publication title
Urine Afamin as a biomarker of lupus nephritis
Copyright © 2025 Lin, Du, Wang, Lai, Yao, Chen, Xu and Sun.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
The association between various biomarkers and the risk of lupus nephritis (LN) has been extensively investigated. However, a dearth of readily available, specific, and sensitive diagnostic biomarkers for LN remains. This study aimed to examine the levels of Afamin in the urine and plasma of patients with systemic lupus erythematosus (SLE) and to evaluate its potential utility for diagnosing LN.
Source: ObjectiveAbstract: What methods does the paper describe?
This study enrolled 31 LN: SLE patients, 31 non-LN: SLE patients, and 27 healthy controls (HC). First, tandem mass tag (TMT): based proteomic screening of urine and plasma (n = 15 per group) identified Afamin as a significantly upregulated protein in LN. Subsequently, ELISA validation confirmed that both uAfamin and pAfamin levels were markedly higher in the LN group. The diagnostic performance of uAfamin for active LN was further evaluated using receiver operating characteristic (ROC) curve analysis.
Source: MethodsAbstract: Results
Levels of both urinary and plasma Afamin were significantly elevated in patients with LN: SLE compared to those with non-LN: SLE. Moreover, uAfamin and pAfamin levels demonstrated robust correlations with multiple clinical indicators of disease activity, including 24h urinary total protein (24hUTP), creatinine, urea, hematuria, pyuria, SLEDAI, and renal SLEDAI. Multivariable linear regression analysis established uAfamin as an independent determinant of renal SLEDAI scores. Consistent with this, ROC curve analysis confirmed that uAfamin possesses a strong capacity to diagnose LN.
Source: ResultsAbstract: Conclusion
The uAfamin level serves as a biomarker for LN, aiding in monitoring disease progression and suggesting a new avenue for personalized treatment strategies.
Source: ConclusionAuthors’ abstract
Objective
The association between various biomarkers and the risk of lupus nephritis (LN) has been extensively investigated. However, a dearth of readily available, specific, and sensitive diagnostic biomarkers for LN remains. This study aimed to examine the levels of Afamin in the urine and plasma of patients with systemic lupus erythematosus (SLE) and to evaluate its potential utility for diagnosing LN.
Methods
This study enrolled 31 LN: SLE patients, 31 non-LN: SLE patients, and 27 healthy controls (HC). First, tandem mass tag (TMT): based proteomic screening of urine and plasma (n = 15 per group) identified Afamin as a significantly upregulated protein in LN. Subsequently, ELISA validation confirmed that both uAfamin and pAfamin levels were markedly higher in the LN group. The diagnostic performance of uAfamin for active LN was further evaluated using receiver operating characteristic (ROC) curve analysis.
Results
Levels of both urinary and plasma Afamin were significantly elevated in patients with LN: SLE compared to those with non-LN: SLE. Moreover, uAfamin and pAfamin levels demonstrated robust correlations with multiple clinical indicators of disease activity, including 24h urinary total protein (24hUTP), creatinine, urea, hematuria, pyuria, SLEDAI, and renal SLEDAI. Multivariable linear regression analysis established uAfamin as an independent determinant of renal SLEDAI scores. Consistent with this, ROC curve analysis confirmed that uAfamin possesses a strong capacity to diagnose LN.
Conclusion
The uAfamin level serves as a biomarker for LN, aiding in monitoring disease progression and suggesting a new avenue for personalized treatment strategies.
Publication and source details
Original title: Urine Afamin as a biomarker of lupus nephritis
Shiyu Lin; Mengru Du; Jie Wang; Peng Lai; Genhong Yao; Weiwei Chen; Xue Xu; Lingyun Sun
Frontiers in Immunology · 2025
* Correspondence: Xue Xu, iamxuxue@163.com; Genhong Yao, yaogenhong@nju.edu.cn; Weiwei Chen, chenweiweinj@163.comThese authors have contributed equally to this work
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T01:31:40.718929+00:00
DOI: 10.3389/fimmu.2025.1696288 · PMC12698515